12:00 AM
 | 
Jun 20, 2011
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 6/17 cls
BTG plc (LSE:BGC) Jefferies Philippa Gardner Upgrade Hold (from underperform) 2% 275.1p
Gardner also raised her target to 240p from 200p after increasing her peak sales estimate for prostate cancer drug Zytiga abiraterone acetate and "increased confidence" in the completion of a rolling BLA to FDA by mid-year for Voraxaze glucarpidase to reduce toxic methotrexate levels due to impaired renal function. Gardner doubled her peak sales estimate for Zytiga to $2.5B based primarily on U.S. pricing....

Read the full 581 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >